Constructive Bio
A synthetic biology company that designs and manufactures proteins with non-canonical amino acids for medicines and materials.
Constructive Bio has raised €67M across 2 funding rounds from 5 investors, most recently a Series A round in Sep 2024. Based in Cambridge, UK; active in Healthtech. Data as of 28 Oct 2026.
Cambridge, UKwww.constructive.bio ↗
Total raised
€67M
€66,526,567
Funding rounds
2
Investors
5
distinct backers
Active since
2022-08
latest 2024-09
Funding by year
EUR raised per yearConstructive Bio — funding by year — interactive chart.
Data table
| Constructive Bio — funding by year | |
|---|---|
| 2022 | €15M |
| 2024 | €52M |
Signals
High confidenceRaise-next likelihood60
base rate 44% for Series A
- ▲ In typical raise window
- ▲ Up-round momentum
Exit likelihood10
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-09-25 | Series A | €52M | Ahren,OMX Ventures,Paladin Capital Group | View deal → |
| 2022-08-15 | Seed | €15M | Ahren,Amadeus Capital Partners,General Inception,OMX Ventures | View deal → |